Cargando…

APOBEC mutational signature predicts prognosis and immunotherapy response in nonsmoking patients with lung adenocarcinoma

BACKGROUND: Lung adenocarcinoma (LUAD) is the most common type of non-small cell lung cancer (NSCLC) with poor survival in advanced stage. Nowadays the rate of nonsmoking patients has dramatically increased and may be associated with the presence of driver mutations. Better understanding of the muta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Jianli, Yang, Xudong, Zhang, Jing, Antonoff, Mara B., Wu, Qianjiang, Ji, Hongfei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088004/ https://www.ncbi.nlm.nih.gov/pubmed/37057114 http://dx.doi.org/10.21037/tlcr-23-150

Ejemplares similares

APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer
por: Wang, Shixiang, et al.
Publicado: (2018)

CD8(+) T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung Adenocarcinoma
por: Zhang, Minghui, et al.
Publicado: (2022)

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
por: Walker, Brian A, et al.
Publicado: (2015)

Prognostic value, immune signature and molecular mechanisms of the APOBEC family members APOBEC1, APOBEC3A, APOBEC3G and APOBEC3H in pancreatic adenocarcinoma
por: Duan, Yunjie, et al.
Publicado: (2022)

Cuproptosis-related signature predicts prognosis, immunotherapy efficacy, and chemotherapy sensitivity in lung adenocarcinoma
por: Wu, Gujie, et al.
Publicado: (2023)

The nonsmokers’ and smokers’ pathways in lung adenocarcinoma: Histological progression and molecular bases
por: Okudela, Koji, et al.
Publicado: (2021)

APOBEC3 signature mutations in chronic lymphocytic leukemia
por: Rebhandl, S, et al.
Publicado: (2014)

Mutation Signatures Including APOBEC in Cancer Cell Lines
por: Jarvis, Matthew C, et al.
Publicado: (2018)

An extended APOBEC3A mutation signature in cancer
por: Langenbucher, Adam, et al.
Publicado: (2021)

Decreased miR-940 expression can predict a negative prognosis in early-stage nonsmoking female lung adenocarcinoma
por: Ma, Qianli, et al.
Publicado: (2021)

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
por: Li, He, et al.
Publicado: (2023)

The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas
por: Saraconi, Giulia, et al.
Publicado: (2014)

The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma
por: Li, Xizhe, et al.
Publicado: (2022)

A lepidic gene signature predicts patient prognosis and sensitivity to immunotherapy in lung adenocarcinoma
por: Nguyen, Thinh T., et al.
Publicado: (2022)

Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis
por: Shu, Jianfeng, et al.
Publicado: (2023)

Cuproptosis and Immune-Related Gene Signature Predicts Immunotherapy Response and Prognosis in Lung Adenocarcinoma
por: Sun, Zihao, et al.
Publicado: (2023)

Uncovering Driver DNA Methylation Events in Nonsmoking Early Stage Lung Adenocarcinoma
por: Zhang, Xindong, et al.
Publicado: (2016)

Constructing an APOBEC-related gene signature with predictive value in the overall survival and therapeutic sensitivity in lung adenocarcinoma
por: Luo, Yu, et al.
Publicado: (2023)

Comprehensive characterization of MUC16 mutations in lung adenocarcinoma for immunotherapies and prognosis: An observational study
por: Liu, Tingjun, et al.
Publicado: (2023)

An APOBEC3 Mutational Signature in the Genomes of Human-Infecting Orthopoxviruses
por: Forni, Diego, et al.
Publicado: (2023)

Erratum: The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas
por: Saraconi, Giulia, et al.
Publicado: (2014)

Prognosis and Immunotherapy Response With a Novel Golgi Apparatus Signature-Based Formula in Lung Adenocarcinoma
por: Jiang, Yupeng, et al.
Publicado: (2022)

Identification of an Exosome-Related Signature for Predicting Prognosis, Immunotherapy Efficacy, and Tumor Microenvironment in Lung Adenocarcinoma
por: Lin, Tao, et al.
Publicado: (2022)

A novel metabolic-immune related signature predicts prognosis and immunotherapy response in lung adenocarcinoma
por: Tang, Xiaolong, et al.
Publicado: (2022)

Identification of N7-methylguanosine related signature for prognosis and immunotherapy efficacy prediction in lung adenocarcinoma
por: Li, Zhouhua, et al.
Publicado: (2022)

A novel immune checkpoints-based signature to predict prognosis and response to immunotherapy in lung adenocarcinoma
por: Sun, Nan, et al.
Publicado: (2022)

A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts
por: Ren, Qianhe, et al.
Publicado: (2023)

A novel methionine metabolism-related signature predicts prognosis and immunotherapy response in lung adenocarcinoma
por: Chang, Qing-Hua, et al.
Publicado: (2023)

A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma
por: Yu, Sheng, et al.
Publicado: (2023)

Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma
por: Zeng, Weibiao, et al.
Publicado: (2023)

Development of somatic mutation signatures for risk stratification and prognosis in lung and colorectal adenocarcinomas
por: Menor, Mark, et al.
Publicado: (2019)

Two Similar Signatures for Predicting the Prognosis and Immunotherapy Efficacy of Stomach Adenocarcinoma Patients
por: Yue, Taohua, et al.
Publicado: (2021)

Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types
por: Chen, Zhishan, et al.
Publicado: (2019)

A Novel Signature of Lipid Metabolism-Related Gene Predicts Prognosis and Response to Immunotherapy in Lung Adenocarcinoma
por: Zhang, Kai, et al.
Publicado: (2022)

Identification and Application of a Novel Immune-Related lncRNA Signature on the Prognosis and Immunotherapy for Lung Adenocarcinoma
por: Zeng, Zhimin, et al.
Publicado: (2022)

A novel zinc metabolism-related gene signature to predict prognosis and immunotherapy response in lung adenocarcinoma
por: Chang, Wuguang, et al.
Publicado: (2023)

Identification of a polycomb group-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma
por: Liu, Lei, et al.
Publicado: (2023)

Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma
por: Wang, Ning, et al.
Publicado: (2023)

Identification and validation of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with lung adenocarcinoma
por: Li, Chunhong, et al.
Publicado: (2023)

Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma
por: Ma, Yiming, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r5qvadeih3pmbmq5usnb9bknfm